Key result
MonoHER pretreatment significantly enhanced the cytotoxicity of doxorubicin in the human liposarcoma cell line WLS-160, reducing the IC50 from 0.016 µM to 0.0075 µM.
Why the study?
Does monoHER sensitize human soft tissue sarcoma cells to doxorubicin-induced apoptosis?
Does monoHER sensitize human soft tissue sarcoma cells to doxorubicin-induced apoptosis?
MonoHER enhances the antitumor activity of doxorubicin in human liposarcoma cells by reducing doxorubicin-induced NF-κB activation.
Answers are grounded in this paper and cite their sources.
May support preclinical exploration of monoHER-doxorubicin combinations in sarcoma; hypothesis-generating and should not yet change practice.
BACKGROUND: Despite therapeutic advances, the prognosis of patients with metastatic soft tissue sarcoma (STS) remains extremely poor. The results of a recent clinical phase II study, evaluating the protective effects of the semisynthetic flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside (monoHER) on doxorubicin-induced cardiotoxicity, suggest that monoHER enhances the antitumour activity of doxorubicin in STSs. METHODS: To molecularly explain this unexpected finding, we investigated the effect of monoHER on the cytotoxicity of doxorubicin, and the potential involvement of glutathione (GSH) depletion and nuclear factor-κB (NF-κB) inactivation in the chemosensitising effect of monoHER. RESULTS: MonoHER potentiated the antitumour activity of doxorubicin in the human liposarcoma cell line WLS-160. Moreover, the combination of monoHER with doxorubicin induced more apoptosis in WLS-160 cells compared with doxorubicin alone. MonoHER did not reduce intracellular GSH levels. On the other hand, monoHER pretreatment significantly reduced doxorubicin-induced NF-κB activation. CONCLUSION: These results suggest that reduction of doxorubicin-induced NF-κB activation by monoHER, which sensitises cancer cells to apoptosis, is involved in the chemosensitising effect of monoHER in human liposarcoma cells.
No takes yet. Share an insight, caveat, or question.
Jacobs et al. (2011) studied Soft tissue sarcoma. monoHER vs. Doxorubicin alone was evaluated on IC50 of growth inhibition by doxorubicin in WLS-160 cells (µM) (p=<0.05). MonoHER pretreatment significantly enhanced the cytotoxicity of doxorubicin in the human liposarcoma cell line WLS-160, reducing the IC50 from 0.016 µM to 0.0075 µM.
Synapse has enriched 10 related papers. Consider them for comparative context: